Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | 3004298 | PO / MO |
The patient took the Vivotif first two doses on consecutive days (yesterday and today); Case reference number US-BN-2025-000933 is a spontaneous case initially received from pharmacist via Communication (reference number: USBAV25-1100) on 12-May-2025 and concern 46-years-old male patient. The patient's medical history and concomitant medication details were not provided. On 11-May-2025, reported as yesterday, the patient took first dose of Vivotif (batch number: 3004298, expiration date: Jul-2026) at an unknown dose, orally for unknown indication. On 12-May-2025, one day after the first dose, reported as today, the patient took second dose of Vivotif (batch number: 3004298, expiration date: Jul-2026) at an unknown dose, orally. As reported, the patient took the Vivotif first two doses on consecutive days (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 46-years-old male patient took first two doses of Vivotif on consecutive days which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 46-years-old male patient took first two doses of Vivotif on consecutive days which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None